This white paper examines the practical challenges of using digital health technologies to create patient-focused endpoints in central nervous system clinical trials. IQVIA explains that although DHTs can improve measurement precision, sensitivity, remote monitoring, and patient stratification, their adoption is limited by complex validation requirements, proprietary devices and algorithms, poor interoperability, large data volumes, and uncertain placement within endpoint hierarchies. The paper recommends integrating DHTs early into clinical development strategies, defining clear concepts of interest, generating evidence for each data-processing step, evaluating device equivalence, and aligning digital measures with established clinical outcome assessments. Careful planning can strengthen

Join for free to read